It could be simply that the effectiveness of 809 levels off in the dose range tested, or it might take a larger trial to see the dose effect. A sc decrease could also become statistically significant when the data were taken from a larger pool of patients.
I doubt that the two drugs compete for fat molecules since the two would be taken after meals. However, if this were the case, Kalydeco (twice daily) can be taken for breakfast and dinner, but 809 (an once-daily drug) can be taken after lunch.
Do you remember when the results of Ph 2A came out, we were discussing whether a mere 1 week of dosing overlap time for the combo was enough. We suggested a longer dosing time. It turned out we were right on that.
If 661 is as safe as 809, it would be a better drug for patients suffering from the lung problems because it distributes better to the lung tissues.
I am looking forward to a more tranquil environment for communication. However, I was able to read your excellent summary of, and comment on, the conference content. When the results from 661 are reported later this year, the noise level will increase again.
I was wondering if you were just waiting out the noise or had retired to a nice tropical island! ;-) thanks for the note--I didn't realize that was the fat soluable/water soluable thing we had discussed earlier, so that make sense.
I'm about to post a hypothesis--1 of 3--others probably tomorrow and next day and would love your take!! But part of it does deal with length of dosing and it seems to be all clicking in my mind now for why this is working now, but your thoughts are so greatly appreciated!!!